Alefacept for psoriasis and psoriatic arthritis.

Abstract	Alefacept is a bioengineered fusion protein of soluble lymphocyte function antigen (LFA-3) with Fc fragments of IgG1. It is marketed in many countries for the treatment of moderate to severe psoriasis. This paper reviews the data supporting the use of alefacept in psoriasis and psoriatic arthritis.
Authors	A B Gottlieb
Journal	Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 64 Suppl 4 Pg. iv58-60 (Nov 2005) ISSN: 0003-4967 [Print] England
PMID	16239390 (Publication Type: Journal Article, Review)
Chemical References	Immunosuppressive Agents Recombinant Fusion Proteins Alefacept
Topics	Alefacept Arthritis, Psoriatic (drug therapy) Combined Modality Therapy Drug Monitoring (methods) Humans Immunosuppressive Agents (therapeutic use) Psoriasis (drug therapy) Randomized Controlled Trials as Topic Recombinant Fusion Proteins (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!